Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Combination model predicts imminent preeclampsia

Ciobanu A et al. Am J Obstet Gynecol. 2019 Feb 7. doi. org/10.1016/j.ajog.2019.01.235

Key clinical point: A competing risks model predicted preeclampsia more effectively than did angiogenic placental growth factor (PlGF) alone or an sFLT/PlGF ratio.

Major finding: The AUROC for preeclampsia at 2 weeks or less before delivery was significantly higher for a combination model (0.975), compared with PlGF (0.900) or the sFLT/PlGF ratio (0.932).

Study details: The data come from a prospective, observational study of 15,247 pregnancies.

Disclosures: The study was supported by a grant from the Fetal Medicine Foundation; Thermo Fisher Scientific provided the reagents and equipment. The researchers had no financial conflicts of interest.

Citation:

Ciobanu A et al. Am J Obstet Gynecol. 2019 Feb 7. doi. org/10.1016/j.ajog.2019.01.235.